Trulicity (dulaglutide) / Eli Lilly - LARVOL DELTA

ANURIA FOLLOWING LEFT RENAL VEIN LIGATION IN A LONE KIDNEY: A SURGICAL MYTH IS VIGOROUSLY CHALLENGED - AN EVOLVING CASE REPORT FROM SEPTEMBER 2025 (ISN-WCN 2026) - "Outpatient medications included Dapagliflozin 10 mg daily, insulin, glipizide 20 mg daily, Losartan 25 mg daily, Prazosin 1 mg at bedtime and Dulaglutide 0.75 mg subcutaneous, weekly.During the open periaortic lymph node biopsy, the left renal vein was ligated to mobilize the inferior vena cava. In solitary kidney patients, the absence of collateral outflow makes ligation particularly dangerous and irreversible renal loss and need for permanent dialysis have been described. Recent studies continue to highlight the variability of renal tolerance and emphasize cautious, individualized operative planning regarding the practice of pre-emptive left renal vein ligation performed intraoperatively to improve surgical exposure and to control bleeding."

Case report • Clinical • Breast Cancer • Diabetes • Diabetic Nephropathy • Hypertension • Metabolic Disorders • Nephrology • Solid Tumor • Type 2 Diabetes Mellitus • Urothelial Cancer

EVALUATION OF DIABETES-RELATED DISTRESS USING THE PAID QUESTIONNAIRE IN A HEMODIALYSIS PATIENT WITH DIABETIC POLYNEUROPATHY (ISN-WCN 2026) - "For diabetes, he had been taking saxagliptin 5 mg once daily and repaglinide 0.25 mg three times daily. After acute pancreatitis, these were discontinued and replaced with GLP-1 receptor agonist dulaglutide 0.75 mg weekly subcutaneously...Given the difficulty of nerve conduction studies [4], simplified diagnostic criteria [1] offer a practical alternative. Clinicians should address both neuropathic severity and diabetes-related distress to optimize care and potentially reduce cardiovascular risk [1,2]."

Clinical • Addiction (Opioid and Alcohol) • Cardiovascular • Diabetes • Diabetic Neuropathy • Diabetic Retinopathy • Genetic Disorders • Metabolic Disorders • Obesity • Orthopedics • Pain • Pancreatitis • Renal Disease • Retinal Disorders • Type 2 Diabetes Mellitus

Weekly Journal Scan: Tirzepatide did not SURPASS the cardiovascular benefits of dulaglutide in type 2 diabetes. (PubMed, Eur Heart J) - No abstract available

Journal • Cardiovascular • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Pharmacist-led management of GLP-1 and GIP/GLP-1 receptor agonists in type 2 diabetes mellitus. (PubMed, Am J Health Syst Pharm) - "Pharmacist-led management of GLP-1 RA or GIP/GLP-1 RA therapy resulted in a greater improvement in HbA1c when compared to usual care."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

GLP-1 receptor agonists and sexual function in women and men: a narrative review of emerging evidence and the need for further research. (PubMed, Sex Med Rev) - "Collectively, preclinical evidence supports inhibitory effects of GLP-1 receptor activation on sexual motivation, whereas human findings are limited and reveal heterogeneous outcomes possibly influenced by gender, metabolic status, GLP-1 RA drug type, and psychosocial factors. Further mechanistic and controlled clinical studies are warranted since there seems to be a divergence between preclinical and clinical data."

Clinical • Journal • Review • Erectile Dysfunction

Exit Interviews Examining Patient Experiences with Tirzepatide and Dulaglutide for Treatment of Type 2 Diabetes in the SURPASS-CVOT Trial (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Clinical • Interview • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Circulating miRNAs as Predictors of Weight Reduction in Type 2 Diabetes Treated with GLP-1 Receptor Agonist Dulaglutide: Secondary Analysis of AWARD-7 Trial (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

The SURPASS-CVOT Retinopathy Substudy: Retinal Status after Treatment with Tirzepatide or Dulaglutide in Patients with Type 2 Diabetes and Risk for Progressive Retinopathy (ADA 2026) - "Available on Friday, May 29, 2026 at 12:00am CDT."

Clinical • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Renal Outcomes of GLP-1 Receptor Agonists and Tirzepatide Across CKD Stages and Metabolic Phenotypes (Type 2 Diabetes and/or Overweight/Obesity): A Scoping Review. (PubMed, Diabetes Ther) - "GLP-1-based therapies demonstrate consistent renoprotective signals across CKD stages and metabolic phenotypes, particularly in type 2 diabetes. Evidence is strongest for semaglutide and dulaglutide, with emerging data for tirzepatide and other incretin-based agents. These findings provide a structured evidence map to inform future consensus and clinical decision-making."

Journal • Review • Cardiovascular • Chronic Kidney Disease • Diabetes • Genetic Disorders • Metabolic Disorders • Nephrology • Obesity • Renal Disease • Type 2 Diabetes Mellitus

Risk of Developing Scarring and Non-Scarring Alopecia with GLP-1 and GLP-1/GIP Agonist Utilization (AAD 2026) - "The treatment cohort included patients who initially used semaglutide, liraglutide, exenatide, dulaglutide, or tirzepatide after 2017. Treated patients were matched 1:1 with non-treated controls based on age, sex, race, type 2 diabetes, and congestive heart failure using propensity score matching...The treatment cohort had a significantly increased risk of developing all alopecia diagnoses (p < 0.0001), including the development of alopecia areata, androgenic alopecia, central centrifugal cicatricial alopecia, lichen planopilaris, frontal fibrosing alopecia, and folliculitis decalvans. These findings suggest GLP-1 and GLP-1/GIP agonists may significantly increase the risk of developing scarring and non-scarring alopecia."

Alopecia • Cardiovascular • Congestive Heart Failure • Dermatopathology • Diabetes • Fibrosis • Heart Failure • Hypertension • Immunology • Lichen Planus • Metabolic Disorders • Type 2 Diabetes Mellitus

GLP-1 receptor agonists-associated skin events: identifying the most common culprits and reactions (AAD 2026) - "Several patients (42%) experienced over three comorbidities, with diabetes, obesity, and hypertension being most common...Out of total alopecia reports, 700 (30.2%) were associated with semaglutide, 534 (23.1%) with liraglutide, 492 (21.3%) with tirzepatide, 304 (13.1%) with dulaglutide, and 284 (12.3%) with exenatide...GLP-1 RAs are associated with various dermatologic AEs, ranging from mild rashes to autoimmune disease. Increased recognition can improve diagnostic accuracy and guide safe therapeutic substitutions."

Alopecia • Cardiovascular • Diabetes • Genetic Disorders • Hypertension • Immunology • Metabolic Disorders • Obesity • Pruritus • Urticaria

Monotherapy Versus Dual Therapy With GLP-1 Agonists in the Management of Hidradenitis Suppurativa: A Literature Review (AAD 2026) - "A literature search of PubMed and Google Scholar (2015–2025) identified studies including case reports, case series, observational analyses, and clinical trials investigating GLP-1 RAs such as liraglutide, semaglutide, and dulaglutide. Direct comparative evidence between approaches remains limited, with existing reports largely based on small cohorts and heterogeneous outcomes. Collectively, these findings underscore the emerging role of GLP-1 RAs in HS management and highlight the need for larger, controlled studies to define their optimal application."

Monotherapy • Review • Dermatology • Diabetes • Genetic Disorders • Hidradenitis Suppurativa • Immunology • Inflammation • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Dermatologic side effects of GLP-1 receptor agonists: A Cross-sectional Analysis (AAD 2026) - "Introduction: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used for the management of diabetes and obesity, with gastrointestinal side effects being the most commonly reported...Search terms included: GLP-1 Receptor Agonist, Semaglutide, Tirzepatide, Liraglutide, Dulaglutide, Exenatide, Lixisenatide, Albiglutide... Dermatologic AEs due to GLP-1 RAs use are relatively uncommon. Injection-site reactions represent the most frequent cutaneous complication, while alopecia, dermatitis, and urticaria are rarely reported. Proactively anticipating and addressing these dermatologic AEs are essential to optimizing patient care and counseling."

Adverse events • Alopecia • Dermatitis • Diabetes • Genetic Disorders • Immunology • Metabolic Disorders • Obesity • Pruritus • Urticaria

The Effect of Specific GLP-1RAs on Wound Healing after Mohs Surgery in Overweight Non-Diabetic Patients (AAD 2026) - "No differences were observed for liraglutide, dulaglutide, exenatide, or tirzepatide. Conclusion Prospective studies are needed to evaluate the biomechanism and effects of GLP-1RAs in the wound healing process in non-diabetic individuals following MMS."

Clinical • Surgery • Fibrosis • Immunology • Infectious Disease • Inflammation • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

A Systematic Review and Meta-Analysis of Efficacy and Safety of Liraglutide in Patients with Type 2 Diabetes Mellitus. (PubMed, Diabetes Metab Syndr Obes) - "When compared with oral semaglutide, exenatide, dulaglutide, lixisenatide, and albiglutide, liraglutide showed comparable efficacy. Liraglutide 1.2 mg showed a numerically lower incidence of nausea and similar rates of vomiting compared with other GLP-1RAs. Liraglutide 1.2 mg and 1.8 mg doses improve weight and glycemic outcomes with a favourable safety profile, supporting its role as an effective therapeutic option for comprehensive management of T2DM with comorbid obesity."

Journal • Retrospective data • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Effects Of Tirzepatide Compared With Dulaglutide On Expanded Cardiorenal Outcomes (ACC 2026) - "Abstract is embargoed at this time."

Late-breaking abstract

HARMONIZED META-ANALYSIS OF GLP-1 RECEPTOR AGONIST CARDIOVASCULAR OUTCOME TRIALS: CONSISTENT REDUCTION IN 3-POINT MACE (ACC 2026) - " To assess GLP-1RA effects on 3-point MACE (CV death, nonfatal MI, nonfatal stroke) and the impact of endpoint harmonization, we meta-analyzed eight placebo-controlled CV outcome trials: ELIXA (lixisenatide), LEADER (liraglutide), SUSTAIN-6 (semaglutide s.c.), EXSCEL (exenatide), HARMONY (albiglutide), REWIND (dulaglutide), PIONEER-6 (oral semaglutide), and AMPLITUDE-O (efpeglenatide). Across >60,000 T2D patients, GLP-1RAs reduced 3-point MACE by ~14%. By harmonizing endpoints and eliminating trial-level variation, this analysis clarified a consistent class effect, contrasting prior heterogeneous reports and reinforcing GLP-1RAs as a cornerstone of ASCVD prevention."

Retrospective data • Cardiovascular • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

DULAGLUTIDE PROMOTES CORONARY PLAQUE STABILIZATION IN PATIENTS WITH TYPE 2 DIABETES: AN OPTICAL COHERENCE TOMOGRAPHY STUDY (ACC 2026) - "GLP-1RA enhances glycemic stability and promotes plaque stabilization in people with T2D, suggesting mechanistic pathways for the cardiovascular protective effect of GLP-1RA."

Clinical • Cardiovascular • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

COMPREHENSIVE OUTCOMES OF GLUCAGON-LIKE PEPTIDE 1 AGONISTS VERSUS TIRZEPATIDE (ACC 2026) - " This study identified 235,916 patients with BMI ≥30 who initiated semaglutide (n=147,870), liraglutide (n=20,635), dulaglutide (n=53,553), or tirzepatide (n=13,858). Compared with other GLP1 agonists, tirzepatide was consistently associated with improved outcomes. These findings highlight its potential to enhance long-term cardiometabolic and neurologic health, supporting its consideration as a preferred therapy for patients with obesity."

Alzheimer's Disease • Cardiovascular • CNS Disorders • Dementia • Genetic Disorders • Myocardial Infarction • Obesity • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Apnea • Sleep Disorder

USE OF ECNOGLUTIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS - A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIAL (ACC 2026) - "The use of glucagon-like peptide-1 receptor agonists, such as ecnoglutide, has an impact on reduction of glycated hemoglobin (HbA1c) and weight, with cardiovascular protection...Three trials, with 904 patients and median follow-up of 32 weeks, assessed ecnoglutide (0.6 mg or 1.2 mg weekly) in comparison with placebo or dulaglutide...Ecnoglutide reduces HbA1c, FPG, weight, and waist circumference in T2DM patients. More RCTs should be performed to corroborate these data."

Retrospective data • Review • Cardiovascular • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Tirzepatide-Induced Morbilliform Drug Eruption: Implications for Rising GLP-1 Agonist Use (AAD 2026) - "Background Glucagon-like peptide-1 (GLP-1) and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists are used for type 2 diabetes and obesity. Generalized drug eruptions are rarely reported, with only two dulaglutide-associated cases described, and none with tirzepatide...A third biopsy showed similar findings, prompting initiation of a topical calcineurin inhibitor, oral doxycycline, a four-week prednisone taper, and six weeks of methotrexate...Dupilumab was started, but the eruption flared following each tirzepatide injection. Ultimately, the eruption resolved completely after tirzepatide discontinuation with a one-week prednisone taper and topical triamcinolone...Diagnosis can be confirmed with positive dechallenge. Management centers on drug cessation, with systemic steroids, topical therapy, antihistamines, or biologics for symptom control."

Atopic Dermatitis • Dermatitis • Diabetes • Genetic Disorders • Immunology • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Exploring the use of GLP-1 and GIP/GLP-1 medications in people on renal replacement therapy, an observational cohort study. (UKKW 2026) - "Thirty-five were on HD (3.1% of 1117 patients on HD) and five on PD (2.6% of 191 patients on PD)...Semaglutide injection was the most prescribed medication (28%), followed by Tirzepatide (23%), Semaglutide tablets (20%), Liraglutide (17%), and Dulaglutide (12%)... GLP-1 and GLP-1/GIP medications are being used in the local RRT population, with over half of the patients showing meaningful weight loss and increases in transplant eligibility. Better integration of dietetic care may enhance outcomes, both in terms of weight loss but also nutritional adequacy."

Observational data • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Metabolic Disorders • Nephrology • Renal Disease • Sarcopenia • Type 2 Diabetes Mellitus

Negotiations with participating drug companies will occur in 2026 and any negotiated and renegotiated prices will become effective January 1, 2028. (CMS Press Release) - "The selected drug list for the third cycle of negotiations is: Anoro Ellipta...Botox; Botox Cosmetic; Cimzia; Cosentyx; Entyvio...Orencia...Trulicity....Xeljanz; Xeljanz XR; Xolair."

Medicare • Allergy • Ankylosing Spondylitis • Asthma • Chronic Obstructive Pulmonary Disease • Crohn's disease • Idiopathic Arthritis • Immunology • Migraine • Psoriasis • Psoriatic Arthritis • Rheumatoid Arthritis • Ulcerative Colitis

Comparative effectiveness of semaglutide and dulaglutide combined with hypocaloric diet in newly diagnosed type 2 diabetes: a retrospective real-world study. (PubMed, BMC Endocr Disord) - No abstract available

HEOR • Journal • Real-world evidence • Retrospective data • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

EFFECTIVENESS AND SAFETY OF GLP-1 RECEPTOR AGONISTS IN PATIENTS WITH WEIGHT RECURRENCE AFTER BARIATRIC SURGERY: A REAL-WORLD STUDY (ISPOR 2026) - "Liraglutide was associated with significant recurrent weight loss at 12 months (18.3% vs 8.4%, p=0.004), whereas semaglutide and dulaglutide showed no statistically significant differences. GLP-1RAs, particularly tirzepatide and liraglutide, were associated with clinically meaningful recurrent weight loss following MBS without an increased risk of adverse events, supporting their use for the management of post-MBS weight recurrence."

Bariatric surgery • Clinical • Real-world • Real-world evidence • Surgery • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus